CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy

Jung Eun Lee, Ji Hee Lim, Yong Kil Hong, Seung Ho Yang

Cancer Research and Treatment. 2018;50(4):1331-1342. Published online 2018 January 10 DOI: https://doi.org/10.4143/crt.2017.466

EXTH-67. HIGH-DOSE METFORMIN PLUS TEMOZOLOMIDE SHOWS INCREASED ANTI-TUMOR EFFECTS IN GLIOBLASTOMA IN VITRO AND IN VIVO COMPARED WITH MONOTHERAPY

Yong-Kil Hong, Seung-Ho Yang

Neuro-Oncology. 2018;20(suppl_6):vi99-vi99

Link1

High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy

Jung Eun Lee, Ji Hee Lim, Yong Kil Hong, Seung Ho Yang

Cancer Research and Treatment. 2018;50(4):1331-1342

Link1

Link2 Link3

P14.79 Randomized phase II trial of Tumor Treating Fields plus radiation therapy plus temozolomide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma

D Limon, F Bokstein, D Blumenthal, C Ben Harush, Z Ram, R Grossman

Neuro-Oncology. 2019;21(Supplement_3):iii86-iii86

Link1

Link2

RTID-12. PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) PLUS RADIATION THERAPY (RT) PLUS TEMOZOLAMIDE (TMZ) COMPARED TO RT PLUS TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)

Rachel Grossman, Dror Limon, Felix Bokstein, Carmit Ben Harosh, Deborah Blumenthal, Zvi Ram

Neuro-Oncology. 2020;22(Supplement_2):ii196-ii196

Link1

Link2

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study

Hiroshi Takahashi, Rimei Nishimura, Daisuke Tsujino, Kazunori Utsunomiya

Journal of Diabetes Investigation. 2018;10(3):714-722

Link1 Link2 Link3 Link4

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)

A. J. Scheen, M. H. Tan, D. J. Betteridge, K. Birkeland, O. Schmitz, B. Charbonnel,

Diabetic Medicine. 2009;26(12):1242-1249

Link1 Link2 Link3

Hispidulin Enhances the Anti-Tumor Effects of Temozolomide in Glioblastoma by Activating AMPK

YanGang Wang, WeiPing Liu, XiaoSheng He, Zhou Fei

Cell Biochemistry and Biophysics. 2014;71(2):701-706

Link1

Link2 Link3 Link4

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo

A. Strube, M. I. Suominen, J. P. Rissanen, D. Mumberg, U. Klar, J. M. Halleen, S.-M. Käkönen

Osteoporosis International. 2010;22(11):2887-2893

Link1

Link2 Link3

Ultrasound Enhanced Anti-tumor Effect of Temozolomide in Glioblastoma Cells and Glioblastoma Mouse Model

Jie Xue, Yuanyuan Wu, Na Liu

Cellular and Molecular Bioengineering. 2018;12(1):99-106

Link1 Link2

Link3

HOUT-18. COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

Gregory Guzauskas, Bruce CM Wang, Erqi Pollom, Volker W Stieber, Lou Garrison

Neuro-Oncology. 2018;20(suppl_6):vi116-vi117

Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.